Trial intelligence / Profile preview

Phase II study of INC280 in EGFR wild-type advanced non-small cell lung cancer with cMET dysregulation

NL-OMON54800Phase 2Active, not recruiting

Sponsor

Novartis

Start

Jun 2015

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1